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FcγRIIB mediates antigen-independent
inhibition on human B lymphocytes
through Btk and p38 MAPK
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Abstract
Background: The inhibitory Fc receptor, FcγRIIB, has emerged as a key negative regulator of B cell activation and
as such is predicted to play an essential role in controlling antibody-mediated autoimmune diseases in humans.
Recent studies have shown that crosslinking the FcγRIIB independently of the B-cell receptor (BCR) results in
apoptosis in both mouse and chicken B cells. However, the human B cell subpopulations that are susceptible
to BCR-independent, FcγRIIB-mediated regulation are not known. How FcγRIIB mediates this inhibition to affect
B cell homeostasis is also not determined.
Results: We isolated naïve B cells, memory B cells and plasma cells (PCs) from peripheral blood of healthy donors
and used differentiated PCs in culture to examine the effects on them by FcγRIIB crosslinking. We showed that
human PCs, memory and naïve B cells all expressed FcγRIIB with expression on PCs being the highest in circulation.
Moreover, they were sensitive to direct inhibition by FcγRIIB through Btk and p38 MAPK. Similarly, PCs resulting
from the antigen-independent differentiation of memory B cells in vitro were inhibited by FcγRIIB cross-linking but
memory B cell activation itself, as measured by proliferation, was unaffected. In contrast, both the proliferation and
differentiation of naïve B cells to PCs were blocked by FcγRIIB crosslinking.
Conclusion: These results suggest a mechanism to control antibody levels involving the differential expression of FcγRIIB
on B cell subpopulations, in which the FcγRIIB functions independently of the BCR to eliminate antibody-secreting
effector cells and inhibit naïve B cell proliferation without compromising the long-lived antigen-specific memory B cells.
Importantly, FcγRIIB requires Btk and p38 MAPK to mediate antigen-independent inhibition in human B cells. Taken
together, our data underscore the importance of antigen-independent inhibition by FcγRIIB in the prevention from
antibody-mediated autoimmune diseases and in the regulation of B cell homeostasis.
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Background
The low affinity Fc receptor, FcγRIIB, is a potent B-cell
inhibitory receptor and as such plays a central role in
controlling antibody-mediated autoimmunity [1, 2]. In
humans, mutations in FcγRIIB have been associated with
systemic lupus erythematosus (SLE) [3, 4], and memory
B cells and PCs in individuals with SLE express lower
levels of FcγRIIB as compared to memory B cells and
PCs in healthy individuals [5], a factor that is suggested
to contribute to disease [6]. The FcγRIIB exerts its
inhibitory effect on B cells via what appears to be two
distinct signaling pathways. When coligated to the B-cell
receptor (BCR) through the binding of antigen-containing
immune complexes (ICs), the FcγRIIB inhibits antigen-
specific antibody responses by blocking BCR signaling.
Such inhibition involves the phosphorylation of the im-
munoregulatory tyrosine inhibitory motif (ITIM) in the
cytoplasmic domain of the FcγRIIB by Lyn, and the re-
cruitment of the lipid phosphatase, SHIP [7–9]. In con-
trast, recent evidence indicates that when clustered
independently of the BCR, the FcγRIIB initiates an ITIM-,
Lyn- and SHIP-independent pathway that triggers apop-
tosis through a mechanism that involves c-Abl family ki-
nases [10, 11]. Thus, the FcγRIIB has the ability to block
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both the BCR-dependent, antigen-driven activation of B
cells as well as antigen-independent, BCR-independent B
cell activation. There is considerable evidence that the
BCR-dependent FcγRIIB inhibitory pathway plays an im-
portant role in regulating the antigen-driven activation of
naïve B cells to proliferate and differentiate to PCs [12].
However, the B cell subpopulations that are susceptible to
BCR-independent, FcγRIIB-mediated inhibition are not as
clearly delineated. It was recently shown, in mice, that
long-lived bone marrow PCs express the FcγRIIB and that
engaging the FcγRIIB by ICs induces these bone marrow
PCs to undergo antigen-independent apoptosis [13]. In
addition, Rahman et al. [14] provided evidence, in mice,
that the FcγRIIB regulates PCs but not germinal center B
cells. Thus, in mice, the accumulation and persistence of
PCs in the bone marrow appears to be regulated by ICs
through the inhibitory FcγRIIB independently of the BCR.
At present, the effect of FcγRIIB crosslinking on the
antigen-independent activation of human B cell subpopu-
lations is not known.
Here we investigate the ability of the BCR-independent
FcγRIIB inhibitory pathway to directly inhibit human per-
ipheral blood PCs and to block the antigen-independent
activation of human naïve and memory B cells to prolifer-
ate and differentiate into PCs in vitro. We provide evi-
dence that the FcγRIIB is most highly expressed on PCs
and that IgG-secreting cells from human peripheral blood
are sensitive to direct inhibition by FcγRIIB-crosslinking.
Crosslinking the FcγRIIB also inhibits PCs resulting from
the antigen-independent differentiation of human mem-
ory B cells but has no direct effect on the antigen-
independent activation of memory B cells to proliferate.
Lastly, we show that both the antigen-independent
proliferation and differentiation of naïve B cells in vitro
are blocked by FcγRIIB crosslinking. Taken together, these
results suggest that the BCR-independent FcγRIIB signal-
ing pathway may play an important role in humans in
acutely controlling antibody levels by inhibiting antibody-
secreting PCs and the activation of naïve B cells without
affecting the long-lived memory B-cell pool, which is
capable to quickly expand and differentiate into PCs




The FcγRIIB-specific mAb AT10 (biotinylated, FITC-
and PE-conjugated) was obtained from Abcam (Cam-
bridge, MA, USA) [15]. Goat IgG and rabbit anti-goat
IgG were used to make ICs as previously described [11].
Mouse IgG1, rabbit peroxidase-anti-peroxidase (PAP)
ICs were purchased from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA). CpG 2006 was
purchased from Santa Cruz Biotechnology (Dallas, TX,
USA). Mouse isotype control mAbs and mAbs specific
for CD19 (SJ25C1), CD45 (HI30), CD27 (L128), CD38
(HB7) and CD14 (M5E2) were purchased from BD Bio-
sciences (San Jose, CA, USA). Recombinant human IL-
21, IL-2 and IL-10 and human sCD40L were purchased
from PeproTech (Rocky Hill, NJ, USA). Antibodies spe-
cific for CD27 (O324), CD19 (HIB19) and CD20 (2H7)
were purchased from eBioscience (San Diego, CA, USA).
Human B cell isolation kit was obtained from BD Biosci-
ences. Staphylococcus aureus Cowan (SAC) and lectin
from Phytolacca Americana (Pokeweed mitogen, PWM)
were obtained from Merck Millipore (Billerica, MA, USA)
and Sigma-Aldrich (St. Louis, MO, USA), respectively.
Carboxyfluorescein succinimidyl ester (CFSE) was acquired
from eBioscience (San Diego, CA, USA). SB203580,
SP600125, Z-VAD-FMK, LFM-A13 and ibrutinib (PCI-
32765) were all purchased from Selleck Chemicals
(Houston, TX, USA).
Isolation and culture of human peripheral blood B cells
Human peripheral blood was obtained from healthy
donors with informed consent and the use of it was
conformed to the approved guidelines established by the
Institutional Review Board of National Taiwan Univer-
sity Hospital (reference numbers: 201005012R and
201307019RINB). Erythrocytes in human peripheral
blood cells were first depleted by lysis buffer (150 mM
NH4Cl, 10 mM KHCO3, 1 mM EDTA, pH 7.4). After
centrifugation the pellets were layered over a Ficoll-
Paque Plus (GE Healthcare, Uppsala, Sweden) gradient
(2,000 rpm, 20 min) to collect lymphocytes at the gra-
dient interface. For flow cytometric analysis cells were
further layered over a fetal calf serum gradient to re-
move platelets (800 rpm, 15 min) to decrease non-
specific binding to mAbs. The cell pellet was washed,
resuspended and cultured on plastic cell-culture
dishes for 30–60 min to remove adherent cells. Non-
adherent cells were harvested and resuspended in PBS
(0.5 % BSA) and B cells were purified by negative se-
lection using the human B cell isolation kit (Merck
Millipore) according to the manufacturer’s protocol.
Biotinylated mouse mAbs specific for CD3 and CD16
(BD Biosciences) were added to the cocktail mAbs to
increase the efficiency of depleting non-B cells. The
resulting B cell populations were 95–98 % pure as
assessed by CD19 and/or CD20 expression. Purified B
cells were further separated into CD27+ memory and
CD27− naïve subsets using CD27 mAb-conjugated
microbeads (Miltenyi Biotec). Alternatively naïve and
memory B cells were obtained by cell sorting gating
on CD19+ cells and then sorting into CD27+ and CD27−
populations using FACSAria cell-sorting system (BD Biosci-
ences). Likewise, PCs were sorted as CD19+CD27+CD38+.
The experimental results from B cells fractionated by mAb-
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conjugated beads or by sorting were comparable. Purified
cell populations (5–10 × 105/ml) were cultured in RPMI-
1640 medium (Thermo Scientific) supplemented with 10 %
heat-inactivated fetal calf serum, 2 mM L-glutamine, 100
U/ml penicillin, 100 mg/ml streptomycin and 50 μM β-
mercaptoethanol. CpG was added at the concentration of
5 μg/106 cells/ml. SAC (at a 1: 10,000 dilution), PWM (at a
1:100,000 dilution), recombinant human IL-2 (10 ng/ml),
IL-10 (10 ng/ml), IL-21 (100 ng/ml) and sCD40L (1 μg/ml)
were added accordingly [16–22].
Flow cytometry
To detect FcγRIIB surface expression, cells were incu-
bated with AT10-FITC. The percentage of dead cells
was measured by 7-aminoactinomycin D (7-AAD).
Multi-color flow cytometry was performed using For-
tessa (BD Biosciences) and analyzed using Flowjo v7.6
(Tristar).
Proliferation and cell division assays
Purified B cells (106/ml) were stimulated in triplicates in
96-well plates in the presence of an isotype control mAb
or AT10 mAb (5 μg/ml) for 48–72 h before adding [3H]
methyl thymidine (1 μCi/well) for an additional 16 h.
Cells were harvested and transferred onto a 96-well filter
paper (PerkinElmer-Wallac, Waltham, MA, USA) and
the radioactivity associated with the filter papers was de-
termined using a β counter. CFSE labeling to detect div-
iding cells was performed following the manufacturer’s
protocol (eBioscience).
ELISPOT assay
Ninety six-well MultiScreen HTS filter plates (Merck
Millipore) were coated with F (ab’)2 goat antibodies spe-
cific for human IgG + IgM antibodies (5 μg/ml) in PBS
at 4 °C overnight. After washing with PBS and blocking
with culture medium, 100 μl fresh medium was added to
each well before adding cells (2-fold serial diluted) for
culture at 37 °C for 4–6 h. Plates were washed with PBS
(0.1 % Tween 20) and then incubated in 100 μl/well PBS
(0.5 % BSA) with biotinylated F (ab’)2 goat antibodies
specific for human μ chain or γ chain (1:5000, Jackson
ImmunoResearch Laboratories) at 4 °C overnight. After
washing, alkaline phosphatase-conjugated streptavidin
(Merck Millipore) was added (100 μl/well) and incu-
bated at ambient temperature for 2–4 h and the plates
were developed using ACE kit (Merck Millipore). After
drying, the plates were scanned and analyzed using
C.T.L. ImmunoSpot scanner and software (version 4).
Statistical analyses
Graphs and histograms were plotted using GraphPad
Prism 5 (San Diego, CA, USA). Statistical analysis was
performed using one-way ANOVA (repeated measures for
paired values) and Turkey’s multiple comparison tests.
Results
The expression of FcγRIIB on peripheral blood PCs,
memory and naive B cells
To determine the populations of human peripheral B
cells that are potential targets of FcγRIIB-mediated
inhibition, we determined the expression of FcγRIIB on
naïve B cells (CD19+CD27−CD38−), memory B cells
(CD19+CD27+CD38−) and PCs (CD19+CD27+CD38+)
by flow cytometry (Fig. 1). The three subpopulations
showed a hierarchical order of FcγRIIB expression
with PCs > memory B cells > naïve B cells (Fig. 1a, b).
This pattern held in the vast majority of cases when
the expression of FcγRIIB was compared between the B
cell populations within each individual donor (Fig. 1c).
These findings suggest that each of these human B cell
populations is potentially susceptible to FcγRIIB regula-
tion and that the outcome of FcγRIIB-crosslinking may
differ between the populations, either quantitatively or
qualitatively, as a consequence of the differences in the
levels of FcγRIIB expression.
FcγRIIB crosslinking inhibits viability of CD19+CD27+CD38+
PCs and in vitro differentiation of PCs
To determine the direct effect of FcγRIIB crosslinking
on ASCs, CD19+CD27+CD38+ PCs were isolated from
human peripheral blood cells as described in Material
and Methods. Taken directly from the peripheral blood
the purified PCs gradually became quiescent and ~30 %
of them underwent spontaneous apoptosis in culture
medium after 24 h. Nevertheless, incubation of these
PCs for 24 h with the presence of FcγRIIB-specific mAbs
AT10, or ICs to crosslink the FcγRIIB resulted in a sig-
nificant reduction of ~15–20 % in cell viability (Fig. 2a).
This circulating population of PCs appeared to contain
mostly IgG-ASCs in a frequency of ~50–100 per 104
CD19+ cells, and many fewer IgM-ASCs (0–50 per 104).
Crosslinking the FcγRIIB also significantly reduced the
number of both IgM- and IgG-ASCs (Fig. 2b). Shown
were the percent of viable cells and the numbers of IgG-
and IgM-secreting cells 24 h after treatment with AT10
mAb for six different individuals. Thus, regardless of
their BCR specificities the ASCs from peripheral blood
are sensitive to direct inhibition by FcγRIIB crosslinking.
Since no exogenous growth factors or cytokines were
added into the medium, this inhibitory effect can be at-
tributed to an increase in apoptosis rather than a block
in proliferation as there was no appreciable change in
cell number in either control or treated cultures (Fig. 2a).
Consistently, the doubling time of human primary B
cells in culture was reported to be ~36 h [23], which was
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longer than the period of 24 h to observe the effect of
AT10 mAb (Fig. 2a and b).
We also examined the effect of FcγRIIB crosslinking
on the differentiation of ASCs from B cells in vitro. Re-
cent evidence indicated that human peripheral blood B
cells express Toll-like receptor 9 (TLR9) and are respon-
sive to TLR9 agonist, CpG ODN, to differentiate into
CD19+CD27+CD38+ PCs in 3 to 5 days in vitro [23, 24].
Consistent with previous findings, we observed that
most (~80–90 %) mature circulating antibody-secreting
PCs died during the first 48 h of culture [23, 24]. Newly
differentiated IgM- and IgG-secreting PCs appeared by
day three in culture at a frequency of approximately 50
PCs per 104 CD19+cells (Fig. 2c) and by day five in
culture the number of IgG-antibody secreting PCs
increased to approximately 100 per 104 CD19+ cells
(Fig. 2c). The presence of the AT10 mAb or ICs signifi-
cantly reduced the number of both IgM- and IgG-ASCs
that resulted from CpG stimulation of PCs measured
after 3 days in culture (Fig. 2c). The addition of IL-2 and
IL-10 or SAC and PWM that are stronger inducers to
BCR to the CpG-containing cultures increased the
resulting number of both IgM- and IgG-ASCs [16] and
in both cases the number of ASCs was reduced signifi-
cantly by the presence of the AT10 mAb but not by an
isotype matched control mAb (Fig. 2c). Taken together
these results indicate that the human ASCs either iso-
lated directly from human peripheral blood or resulting
from the differentiation of PCs in vitro are sensitive to
inhibition by FcγRIIB crosslinking independent of BCR.
The effect of FcγRIIB crosslinking on the antigen-
independent differentiation of B cells to PCs
Human B cells have been shown to respond to the TLR9
agonist, CpG, by proliferating and differentiating into
antibody secreting PCs. Bernasconi et al. [17, 18] re-
ported that CpG single agent activated IgM memory B
cells (CD19+CD27+IgG−) and switched memory B cells
(CD19+CD27+IgD−IgM−) to proliferate and differentiate
into antibody secreting PCs, but had little effect on naïve
B cells (CD19+CD27−). We determined the effect of
crosslinking the FcγRIIB on the differentiation of puri-
fied CD19+ peripheral blood B cells to PCs in response
to CpG, using the ICs. The highly purified CD19+ per-
ipheral blood B-cell population contained less than
0.5 % CD38+ PCs by flow cytometry (Fig. 3) and no
ASCs by ELISPOT analyses after 3 days in culture (data
not shown). Culturing these purified B cells with CpG
induced the differentiation to CD19+CD27+CD38+ PCs
over a 5-day culture as measured by flow cytometry
(Fig. 3). In the absence of CpG no PCs were detected in
the 5-day cultures (data not shown). In the presence
of CpG, 7.9 to 8.1 % of the cells recovered from the
5 day cultures were PCs and this number was signifi-
cantly decreased to 3.5 to 4.2 % by the presence of
the AT10 mAb or ICs in the 5-day cultures. An iso-
type matched control mAb had no effect on the
CpG-induced generation of PCs. Consistently, in the
presence of CpG the reduced number of PCs by
AT10 mAb or ICs appeared to correlate to the de-
crease of ASCs (Fig. 2c and Fig. 3).
a b c
Fig. 1 Human memory B cells, naïve B cells and PCs express FcγRIIB. a B cells were first gated by CD45+CD19+ and further gated to CD27−, CD27+CD38−
and CD27+CD38+ subsets for their expression levels of FcγRIIB . A representative histogram of the mean fluorescence intensity (MFI) of one donor is
shown. b A scatter dot plot (mean ± SEM) of the expression levels of FcγRIIB of the three subpopultions of B cells from 21 donors is shown. The asterisks
indicated that the comparisons are statistically significant (P< 0.01). c The FcγRIIB expression levels of memory B cells, naïve B cells and PCs for individual
donors are shown
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The effect of crosslinking the FcγRIIB on the differen-
tiation of CD19+ B cells in response to CpG was also de-
termined by an ELISPOT assay, capturing antibodies
secreted by PCs using either IgM- or IgG-specific
antibodies. CpG induced the differentiation of both
IgM- and IgG-secreting PCs, suggesting that both IgM
memory B cells and switched memory B cells were
activated to differentiate to PCs. In the absence of CpG
few viable cells and no antibody secreting PCs were re-
covered from the 5-day cultures (data not shown). The
addition of the AT10 mAb reduced the numbers of
both IgG- and IgM-secreting PCs in cultures in a dose-
dependent fashion as compared to an isotype matched
nonspecific control mAb (Fig. 4). The average of the
results from B cells purified from several individual
donors showed that crosslinking the FcγRIIB resulted
in a significant decrease in the number of IgM- and
IgG-secreting PCs (Fig. 4, top). An analysis of each
individual donor showed a large individual to individual
variation in the number of PCs that resulted from CpG
stimulation of B cells but for each individual crosslink-




Fig. 2 Crosslinking FcγRIIB inhibits cell viability of purified primary PCs and subsequent PC differentiation in vitro. a Purified PCs (106/ml) were
cultured for 24 h in the absence (circle) or presence of various doses (2–10 μg/ml) of isotype (squares) or AT10 (filled squares) mAbs. The number
and percentage of dead cells were determined by staining with 7-AAD and side scattering using flow cytometry. b Primarily isolated CD19+ B
cells (106/ml) were cultured for 24 h as in (a) in 96-well ELISPOT plates as described in Methods. c Purified B cells from 6 donors were cultured
as in (b) with the addition of CpG (5 μg/ml) alone, CpG + IL-2 + IL-10 or CpG + SAC + PWM for three or five days without antibody or in the
presence of an isotype matched control mAb or AT10 mAb (5 μg/ml). The asterisks indicate that the differences between the groups compared
are statistically significant (P < 0.05)
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(Fig. 4, bottom). FcγRIIB crosslinking did not have a
significant effect on the overall cell numbers or cell via-
bility in culture (data not shown), suggesting that the
effect of FcγRIIB crosslinking may be at the level of the
relatively small population of newly generated PCs.
FcγRIIB crosslinking reduces the number of PCs resulting
from the differentiation of both naïve and memory B cells
The effect of FcγRIIB crosslinking on the antigen-
independent, CpG-induced differentiation of memory B
cells and naïve B cells to PCs was tested. To do so,
purified peripheral blood CD19+CD38− B cells were
separated into CD27+ memory and CD27− naïve B cell.
Memory and naïve B cells were incubated with CpG in
the presence of graded concentrations of either AT10
mAb or an isotype matched control mAb (Fig. 5). CpG
alone induced the differentiation of both IgG- and IgM-
secreting PCs from memory B cells from the nine
individual donors analyzed and the number of PCs was
reduced by AT10 mAb in a dose dependent fashion but
not by the isotype matched control mAb. The AT10
mAb was effective in reducing the number of IgM- and
IgG-secreting PCs at 5 μg/ml. Naïve B cells were only
weakly responsive to CpG as described previously by
Bernasconi et al. [17, 18] and Jiang et al. [19] and most
of the resulting PCs secreted IgM (Fig. 5). The number
of IgM-secreting PCs was reduced by the AT10 mAb
with the largest decrease observed at 10 μg of AT10.
We also tested the ability of the FcγRIIB to reduce the
number of PCs resulting from the response of B cells to
combinations of CpG and other mitogens, cytokines and
BCR agonists that have been reported to influence the
response of naïve and memory B cells to CpG (Fig. 6).
Consistent with previously reported by Jiang et al. [19],
CpG alone induced naïve B cells into more IgM-ASCs
than IgG-ASCs in a 5-day culture (Fig. 6). Bernasconi
Fig. 3 FcγRIIB crosslinking reduces the number of CD27+CD38+
purified PCs that differentiate from BCR-independent activation of B
cells. Purified B cells (105/ml) were cultured with CpG (5 μg/ml) in
the absence or presence of rabbit PAP ICs (5 μg/ml) for five days.
The percentage of CD27+/hiCD38+ cells by flow cytometry is shown
as a histogram before and after the 5-day culture from five donors.
The asterisk indicates statistical significance of the difference between
the two groups compared (P < 0.05)
Fig. 4 FcγRIIB crosslinking reduces the number of antibody-secreting PCs resulting from BCR-independent activation of B cells. Purified B cells
were treated with CpG (5 μg/ml) without additional antibody or in the presence of an isotype matched control mAb or AT10 mAb in graded
concentrations (0, 1, 2.5, 5 or 10 μg/ml) for five days. ELISPOT analyses were performed to measure total IgM- and IgG-antibody-secreting PCs.
Data are shown as an average of all individuals analyzed (top) or for individual donors (bottom). The asterisks indicate that the differences
between the groups compared are statistically significant (P < 0.05)
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Fig. 5 FcγRIIB crosslinking reduces the number PCs resulting from the BCR-independent differentiation of CD27+ memory and CD27− naïve B
cells. CD27+ and CD27− B cells from eight donors were treated with CpG as in Fig. 4 at various concentrations of isotype matched control or
AT10 mAbs (0, 2, 5, or 10 μg/ml) for five days. The number of IgM- and IgG-antibody-secreting PCs was determined by ELISPOT assay. The
asterisks indicate that the differences between the groups compared are statistically significant (P < 0.05)
a b
Fig. 6 FcγRIIB crosslinking reduces the number of PCs that result from the differentiation from CD27+ memory and from CD27− naïve B cells
to a variety of stimuli. a CD27+ memory B cells or b CD27− naïve B cells were incubated without additional antibody or in the presence of an
isotype matched control mAb or AT10 mAb (5 μg/ml) and either CpG (5 μg/ml) alone, CpG + IL-2 + IL-10, CpG + F (ab’)2 fragment of anti-Ig,
CpG + SAC + PWM or IL-21 + sCD40L. The number of IgM- and IgG-antibody-secreting PCs was determined by ELISPOT assay. The asterisks indicate
that the differences between the groups compared are statistically significant (P < 0.05)
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et al. showed that the addition of the cytokines IL-2
and IL-10 to the CpG-containing cultures increased the
numbers of PCs produced from memory B cells and also
resulted in a limited differentiation of naïve B cells [18, 20].
The addition of IL-2 and IL-10 to CpG-containing cultures
significantly increased the number of both IgM- and IgG-
secreting PCs and this number was reduced by the AT10
mAb. We also tested the effect of F (ab’)2 anti-Ig in com-
bination with CpG on the differentiation of memory B cells
as Bernasconi et al. had shown that BCR crosslinking influ-
enced the response of IgM memory and naïve cells to CpG
[18]. Incubating memory B cells with CpG and F (ab’)2
anti-Ig resulted in an increase in the IgM-secreting PCs as
compared to CpG alone but had no effect on the IgG-
secreting PCs, suggesting that crosslinking the BCR only af-
fected the activation of IgM memory B cells. Crosslinking
the FcγRIIB decreased the number of PCs under these con-
ditions. Crotty et al. [21] showed that a combination of
CpG and S. aureus Cowan (SAC) and Pokeweed mitogen
(PWM) activated memory B cells (CD19+CD27+) to differ-
entiate to IgG secreting PCs. Culturing memory B cells
with CpG in combination with SAC and PWM induced an
increase in both IgM- and IgG-producing PCs over CpG
alone and the AT10 mAb decreased the number of PCs in
each case. Lastly, a combination of IL-21 and sCD40L in-
duced memory B cell differentiation exclusively to IgG-
secreting PCs [22] and the number of IgG-secreting PCs
was blocked by FcγRIIB crosslinking. These findings indi-
cate that the antigen-independent activation of memory B
cells to differentiate to PCs by a variety of different stimuli
is inhibited by FcγRIIB crosslinking. Given that PCs are
themselves inhibited by FcγRIIB crosslinking, the simplest
interpretation of these results is that the FcγRIIB acts to in-
hibit the newly generated PCs rather than blocking the acti-
vation of the memory B cells themselves.
Naïve B cells differentiated primarily into IgM-secreting
PCs in response to all stimuli tested [18] with the excep-
tion of IL-21 and sCD40L that promotes isotype switching
[22] and in each case the number of PCs was decreased in
the presence of AT10 mAb but not an isotype matched
control mAb (Fig. 6). The effect of AT10 mAb was also
tested on PCs differentiated by IL-21 in combination with
sCD40L, conditions that induced isotype switching in B
cells [22]. These culture conditions yielded exclusively
IgG-secreting PCs and these IgG-ASCs were reduced by
the AT10 mAb but not the isotype matched control mAb.
These results suggest that the PCs differentiating from
naïve B cells are inhibited by FcγRIIB crosslinking.
FcγRIIB crosslinking triggers apoptosis of human B cells
through Btk and p38 MAPK
We next investigated the molecular mechanism for the
antigen-independent apoptosis induced by FcγRIIB. Since
Pearse et al. reported that FcγRIIB crosslinking triggers
apoptosis through Btk and JNK in chicken DT40 B cells
[10], we first examined this possibility with two selective
Btk inhibitors, LFM-A13 and ibrutinib, both of which sig-
nificantly blocked apoptosis induced by ICs to a similar
degree compared to controls. The reversal of FcγRIIB-
mediated inhibition was most apparent in PCs (Fig. 7a).
This is consistent with the fact that PCs have the highest
expression level of FcγRIIB, thereby conferring the highest
induction of apoptosis among circulating B cells (Figs. 1
and 2). To further investigate the signaling intermediaries
downstream of Btk, we treated naïve, memory B cells and
PCs with either SP600125, a JNK inhibitor or SB203580, a
p38 MAPK inhibitor in the presence of ICs for 24 h.
Unlike previously reported in DT40 chicken B cells [10],
the p38 MAPK, but not JNK was involved in FcγRIIB-
mediated apoptosis in human B cells (Fig. 7b).
a
b
Fig. 7 Crosslinking FcγRIIB triggers apoptosis through Btk and p38
MAPK in human B cells. a Purified naïve, memory B cells and PCs
(105/ml) from seven donors were each treated with 10 μg/ml of ICs
in the presence of either 2 μM of LFM-A13 or 10 nM of ibrutinib
for 24 h. Apoptotic cells were determined by Annexin V staining
(Biolegend) using flow cytometry. b Three subsets of purified
human B cells were treated separately in the absence or presence of
10 μg/ml ICs with addition of either 5 μM of SP600125 or 5 μM of
SB203580 for 24 h. Apoptotic cells were measured and analyzed as
in a. The asterisks indicate that the differences between the groups
compared are statistically significant (P < 0.05)
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The effect of crosslinking the FcγRIIB on naïve and
memory B cell proliferation
We tested the effects of crosslinking the FcγRIIB on the
proliferative responses of CD19+CD27+CD38− memory
B cells and CD19+CD27−CD38− naïve B cells to the
same combinations of CpG, cytokines and BCR agonists
assessed above in Fig. 6. Memory B cells proliferated
over a 2-day period to CpG in combination with IL-2
plus IL-10, F (ab’)2 anti-Ig or SAC plus PWM (Fig. 8a).
The response in each case was refractory to the effects
of the AT10 mAb even at high antibody concentrations
(10 μg/ml) (data not shown). Moreover, in the presence
of F (ab’)2 anti-Ig to crosslink BCR but absence of any
differentiation agents assessed above, memory B cells
showed no appreciable inhibition by ICs, either (Fig. 8b).
These findings are consistent with the interpretation of
the results above, namely that the FcγRIIB does not act
at the level of the activation of memory B cells, which
are known to be quiescent, progenitor cell-like and less
responsive to mitogenic stimuli [25], but rather inhibits
the resulting PCs.
Naïve B cells proliferated over a 5-day period to vary-
ing degrees in response to CpG alone or in combination
with SAC plus PWM, IL-2 plus IL-10 or F (ab’)2 anti-Ig.
Treatment with CpG in combination with SAC and PWM
or with CpG and F (ab’)2 anti-Ig resulted in the greatest
proliferative responses and these were significantly blocked
by the AT10 mAb as compared to the isotype matched
control mAb (Fig. 8a). Likewise, naïve B cells proliferated in
response to F (ab’)2 anti-Ig alone but this was inhibited by
ICs (Fig. 8b). AT10 had little effect on the naïve B cell pro-
liferative responses to CpG alone or to CpG in combination
with IL-2 and IL-10. This is likely because CpG mainly pro-
motes differentiation rather than proliferation of human B
cells in culture [18]. The selective effect of FcγRIIB cross-
linking on the responses of naïve B cells to the different
stimuli may reflect differences in either the quality or mag-
nitude of the response. Taken together these results provide
evidence that memory B cell responses are refractory to
FcγRIIB regulation in contrast to naïve B cell responses that
are sensitive to FcγRIIB inhibition in proliferation.
Discussion
The FcγRIIB has been shown to serve as a critical per-
ipheral checkpoint to regulate the levels of antibody and
results indicate that the FcγRIIB has the ability to inhibit
B-cell responses independently of the BCR. Recent
studies have clarified which B-cell subpopulations are
susceptible to BCR-independent FcγRIIB regulation in
mice. Xiang et al. [13] demonstrated that the FcγRIIB is
expressed on long-lived PCs and that these cells undergo
apoptosis following FcγRIIB engagement by ICs and
Rahman et al. [14] showed that in mice PCs but not ger-
minal center B cells are regulated by the FcγRIIB. These
a
b
Fig. 8 FcγRIIB inhibits the proliferation of CD27− naïve B cells but not CD27 + memory B cells. a CD27+ and CD27− B cells (106/ml) were cultured for
two days before the addition of 3[H] methyl thymidine for another 16 h. Antibodies (5 μg/ml) and stimuli were added to cells in the beginning of
culture as in Fig. 6. A representative histogram of more than 3 donors was shown. The asterisks indicate that the differences between the groups
compared are statistically significant (P < 0.05). Similar results were obtained when cells were cultured for 1–2 more days before adding 3[H] methyl
thymidine. b CD27+ and CD27− B cells (105/ml) from six donors were culture for 48 h in the presence of 2 μg/ml of F (ab’)2 anti-Ig (IgM + IgG + IgA,
Jackson Immunoresesearch) with (open circle) or without (closed circle) 10 μg/ml of ICs. Cells with decreased green fluorescence, indicative of cell
division, were counted using flow cytometry and the absolute number (× 102) was plotted as the Y-axis. The horizontal bar in each group represents
mean of subjects and the asterisks indicate that the differences between the groups compared are statistically significant (P < 0.05)
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finding are important as they offer a mechanism by
which immunization and the resulting formation of ICs
can reduce the number of pre-existing PCs and thereby
create space for new PCs in the limited microenviron-
ments of the bone marrow that support PC survival.
Here we show that the FcγRIIB is expressed on human
peripheral blood PCs as well as on naïve and memory B
cells and that crosslinking the FcγRIIB inhibits human
ASCs isolated directly from peripheral blood as well as
PCs that resulted from the antigen-independent differen-
tiation of human memory B cells. We also demonstrate
that the signals transduced by FcγRIIB to exert antigen-
independent inhibition require Btk and p38 MAPK.
Lastly, we show that both the antigen-independent pro-
liferation and differentiation of naïve B cells in vitro are
blocked by FcγRIIB crosslinking. Our studies suggest
that the FcγRIIB may play an important role in humans
in acutely controlling antibody levels by inhibiting anti-
body secreting PCs and the activation and proliferation
of naïve B cells. These findings also underscore a crucial
mechanism to control B cell homeostasis through the
peripheral checkpoints on human PCs and naïve B cells
by a negative feedback determined by circulating anti-
body levels.
Recently it has been shown that polyclonal stimulation
through TLRs in the absence of antigen triggers memory
B cells to expand and differentiate into PCs providing a
mechanism by which a long-lived PC can be continually
replenished throughout an individual’s lifetime [17].
However, with the continuous generation of antibody-
secreting PCs it is not clear how the levels of antibodies
are controlled after reaching sufficient or perhaps even
dangerous levels. Our findings that FcγRIIB crosslinking
inhibited PCs generated from memory B cells in culture
but had no effect on memory B cell proliferation sug-
gests a mechanism by which the FcγRIIB acutely
regulate antibody levels without affecting the memory
B-cell pool.
Here we also show that although naïve B cells, mem-
ory B cells and PCs all express FcγRIIB, they do so at
different levels with the lowest expression of FcγRIIB on
naïve B cells and the highest levels on PCs. In general, in
immune cells the FcγRIIB is coupled with activating re-
ceptors to balance the outcome of responses to complex
multiple receptor engagements. Thus, the different levels
of the FcγRIIB on naïve B cells, memory B cells and PCs
may relate to the function of the FcγRIIB in controlling
the particular activating receptors expressed in each cell
type. The relatively high FcγRIIB expression on PCs may
play an important role in triggering apoptosis to achieve
homeostatic control. Importantly, we demonstrate that
the underlying mechanisms of antigen-independent apop-
tosis through FcγRIIB depend on Btk and p38 MAPK in
the human B cells. Although we previously showed that c-
Abl family kinases are essential for FcγRIIB-mediated
apoptosis in mouse A20 B cells [11], the c-Abl’s substrate
motif (Y264QRP) on mouse FcγRIIB appears not con-
served in the counterpart of human receptor (Y258PEC).
This explains no effect of imatinib, a c-Abl inhibitor, on
FcγRIIB-mediated apoptosis in human B cells (data not
shown). Meanwhile, this result raises an interesting ques-
tion on how and why this divergence occurs during the
evolution of adaptive immunity. One additional caveat is
that although there is a ~10–15 % less of apoptosis in-
duced by ICs (Fig. 2a) than that of chicken DT40 B cells
transfected with the mouse FcγRIIB for overexpression
[11], the magnitude in apoptosis induction of these two
cell types is both significant. This is also consistent with
the notion that apoptosis mediated by FcγRIIB depends
on the signal strength as we previously proposed [11].
Recent studies in mice have underscored the import-
ance of the level of FcγRIIB expression in B cells in the
regulation of antibodies levels. FcγRIIB-deficient mice
show an increased accumulation of Ig-secreting cells in
the spleen and an enhanced antibody response [12, 24,
26] and eventually die of a lupus-like glomerulonephro-
pathy. Lupus-prone mice often down-regulate the ex-
pression of FcγRIIB and the resulting defects can be
reversed by increasing FcγRIIB expression levels in B
cells [27]. In humans, Mackay et al. [6] showed that per-
ipheral blood CD27+ memory B cells express higher
levels of FcγRIIB as compared to naïve B cells but that
this level of FcγRIIB is considerably decreased on mem-
ory B cells from SLE patients. In addition, Su et al. [5]
provided evidence that the expression levels of the
FcγRIIB were decreased in memory B cells and PCs in
individuals with active SLE as compared to normal con-
trols. The decreased levels of FcγRIIB correlated with
decreased levels of FcγRIIB-mediated suppression of
BCR-induced calcium responses demonstrating a link
between the level of FcγRIIB expression in human B
cells and inhibitory activity. Xiang et al. [13] also showed
that a multiple myeloma cell line with low FcγRIIB ex-
pression levels was resistant to apoptosis and that the
susceptibility was restored when FcγRIIB surface expres-
sion was increased, indicating a link between the surface
expression levels of FcγRIIB and the functional out-
comes of crosslinking. We show here that the levels of
FcγRIIB expression on B cells vary as much as six fold
between individuals. The factors that influence the ex-
pression of FcγRIIB on B cells among healthy donors are
largely unknown. It has been reported that IL-4 reduces
the expression of FcγRIIB on B lymphocytes and may
play a role in Th2 response in mice [28]. It would be of
great interest to determine the intrinsic and extrinsic
factors that modulate the expression of FcγRIIB as these
may hold the keys to treatment of autoimmune diseases.
In light of the findings of Xiang et al. [13] and those
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presented here, selective modulation of FcγRIIB expres-
sion on PCs may represent a new therapeutic approach
to antibody-mediated autoimmune diseases as previously
suggested [29]. One important caveat is that neither T
cells nor NK cells express FcγRIIB and this gives an
advantage to modulate humoral immunity through
FcγRIIB with little or no impact on the cellular im-
munity. Lastly, our findings that FcγRIIB functions in-
dependently of the BCR to eliminate PCs and inhibit
naïve B cell activation while preserve the long-lived
memory B cells supports its safe clinical use not only
in targeting B cells for the treatment of autoimmune
diseases, e.g. SLE, but also in suppressing autoantibody-
mediated destruction to tissues or cells by intravenous
immunoglobulin therapy (IVIg), e.g. immune thrombocy-
topenic purpura. Under these conditions, administration
of either targeting mAbs or polyclonal gamma globulins
acutely introduces a high level of antibodies in circulation.
Despite the presence of a risk to inadvertently induce
antigen-independent inhibition by FcγRIIB, memory B
cells can be selectively preserved for replenishment to
maintain B cell homeostasis. In addition, patients with sys-
temic lupus erythematosus down-regulate the surface ex-
pression of FcγRIIB on memory B cells and PCs, leading
to uninhibited expansion of B cells and autoantibody pro-
duction [5, 6]. Our data strongly support a crucial role of
FcγRIIB to function in the elimination of autoreactive B
cells to prevent from antibody-mediated autoimmune
diseases and further underscore the importance of
antigen-independent inhibition by FcγRIIB as a peripheral
checkpoint in human B cells. Namely, lower expression of
FcγRIIB not only allows autoreactive PCs to break toler-
ance but also lowers the threshold for them to activate
and expand, thereby allowing secretion and accumulation
of more autoantibodies to form ICs that can deposit in tis-
sues, e.g. the kidney, to cause damage and inflammation.
It is then conceivable that restoration of the expression
level of FcγRIIB on B cells may be beneficial for patients
with SLE to alleviate lupus nephritis in that circulating ICs
can then self-eliminate autoreactive PCs through
apoptosis. Indeed, partial restoration of the expres-
sion level of ~40 % of FcγRIIB on B cells by retro-
viral transfection is sufficient to restore tolerance
and ameliorate disease activity in lupus mice [30].
Since PCs are most sensitive to apoptosis triggered
by FcγRIIB (Fig. 7) [13, 14] targeting FcγRIIB likely
will affect PCs effectively, including those resident in
the bone marrow.
Conclusion
These results provide evidence that human peripheral
blood PCs and naïve B cells but not memory B cells are
main targets of FcγRIIB’s antigen-independent regula-
tion. This observation suggests a mechanism by which
antibody levels can be acutely regulated by ICs during
antibody responses while maintaining B cell homeosta-
sis. Moreover, our findings indicate that the graded
expression levels of FcγRIIB in B cell subpopulations
(PCs >memory cells > naïve cells) dictate the outcomes
of FcγRIIB-mediated inhibition independent of BCR and
provide new insights into safe use of antibody targeted
therapy in autoimmune diseases, e.g. SLE. More import-
antly, we demonstrate for the first time that antigen-
independent inhibition by FcγRIIB is mediated by Btk
and p38 MAPK in human B cells. These findings in
humans also extend our previous work on mouse B cells
and further underscore the importance of antigen-
independent FcγRIIB regulation of antibody responses in
humans since a failure of FcγRIIB to mediate apoptosis
of PCs might result in susceptibility to systemic lupus er-
ythematosus [5, 6]. Taken together, FcγRIIB may be con-
sidered as a new drug target for selective modulation in
the treatment of antibody-mediated autoimmune diseases.
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